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In this issue of Cell Stem Cell, Zhao et al. (2014) and Schu¨rch et al. (2014) describe two new stem cell mech-
anisms underlying protective responses to infection. In response to inflammatory signals, HSPCs and MSCs
produce cytokines that stimulate HSC mobilization and differentiation toward innate immune cells at the
expense of adaptive immune lineages.Adaptive immunity is mediated by lym-
phocytes, which are relatively long lived
cells and can replenish themselves by
division. In contrast, bone marrow
hematopoietic stem cells (HSCs) must
constantly produce appropriate numbers
of nonlymphoid innate effector cells for
host defense. Moreover, they must be
able to quickly ramp up the process in
response to infections. While this phe-
nomenon has long been known and is
assumed to promote organismal survival
(Metcalf, 1971), two studies appearing in
this issue of Cell Stem Cell provide new
insights regarding the underlying mecha-
nisms (Zhao et al., 2014; Schu¨rch et al.,
2014).
Some pathogens perturb blood cell
formation by actually infecting cells
within the bone marrow; however, the
focus of the recent studies is on pro-
cesses commonly referred to as ‘‘emer-
gency’’ or ‘‘demand-adapted’’ hemato-
poiesis (Takizawa et al., 2012), which
can be modeled by bacterial or viral
infection in mice. Infection simulated
with injections of E.-coli-derived lipo-
polysaccharide (LPS), a membrane
polysaccharide expressed in all Gram-
negative bacteria, would seem to be a
simple model of emergency hematopoie-
sis, but numerous host responses come
into play and can be difficult to dissect.
LPS is a ligand for Toll-like receptor 4
(TLR4), which is expressed on immune
cells and stimulates their activation.
Hematopoietic stem and progenitor cells
(HSPCs) are also known to express func-
tional TLRs. Indeed, within 1 hr after
injection, LPS permeates the bone
marrow and binds to TLR4 on HSPCs
(Nagai et al., 2006). TLR4 activation
stimulates hematopoietic stem cell cycle
entry, mobilization to organs such as thespleen, evacuation of B lineage lymphoid
cells from the marrow, and redirection of
progenitors to nonlymphoid fates. The
latter phenomenon can be demonstrated
with purified cells maintained under
defined culture conditions (Nagai et al.,
2006), and the overall outcome is
myeloid cell production at the expense
of lymphopoiesis.
Engaging TLR on individual progenitors
might be sufficient to initiate their division
and redirection toward generation of
innate effector cells. However, in other
circumstances, bystanders are probably
recruited via locally released cytokines.
Paracrine responses to LPS have been
documented in vivo and nonhemato-
poietic stromal elements can also be
sources of factors (Takizawa et al., 2012).
Baltimore and colleagues have now
used an NF-kB reporter system to confirm
that functional TLR4 as well as TLR2 are
present on hematopoietic stem cells
(HSCs) and HSPCs (Zhao et al., 2014).
Of even greater importance, a single-cell
proteomics approach revealed that sub-
sets of short-term HSCs and multipotent
progenitors make large amounts of cyto-
kines in response to stimulation with TLR
ligands. Indeed, they were more efficient
in producing growth and differentiation
factors than mature cells were. Further-
more, mouse models with both reduced
and exacerbated NF-kB signaling were
used to show that the amounts of cyto-
kines produced could be dialed up and
down with changes in NF-kB pathway
activity. Neutralization and knockout
experiments indicated that GM-CSF,
TNF, and especially interleukin-6 (IL-6)
accounted for most of the escalated
nonlymphoid cell production.
IL-6 is a multifunctional cytokine, and
neutralization of its receptor representsCell Stem Ceeffective therapy for many inflammatory
diseases. Coming from a completely
different direction, Offenbein and col-
leagues found another way that IL-6 par-
ticipates in emergency hematopoiesis
(Schu¨rch et al., 2014) (Figure 1). Again,
the study began with a model system.
Cytotoxic T lymphocytes (CTL) from
T cell receptor transgenic mice were iso-
lated and activated by transfer to other
transgenic mice with ubiquitous expres-
sion of the complementary antigen.
There was a modest but consistent
myelopoietic response in the recipient
mice that the investigators used to their
advantage. They assumed correctly
that the CTL produced interferon
gamma (IFNg), which in turn drove mye-
lopoiesis. However, when chimeric mice
generated from transplanting antigen-
specific CTLs into a reactive host were
used, they discovered an unexpected
mechanism. That is, radioresistant, non-
hematopoietic cells with functional IFNg
receptors, rather than myeloid progeni-
tors, were responding to the CTL-
produced factor. A bone marrow fraction
that was clearly induced by IFNg
contained mesenchymal stem cells
(MSCs), and they appeared to predomi-
nantly produce IL-6. Indeed, IFNg did
not cause emergency myelopoiesis in
IL-6-deficient mice.
While these findings were also repli-
cated in viral infection models, some
aspects should be clarified in future
studies. For example, IL-6 can block the
earliest steps in lymphopoiesis (Maeda
et al., 2005) but there were no signs that
this lineage was affected in CTL-injected
animals. Also, levels of two transcription
factors known to drive myelopoiesis, C/
EBPa and Runx1, actually declined in
hematopoietic cells of IFNg-treated mice.ll 14, April 3, 2014 ª2014 Elsevier Inc. 415
Figure 1. BoneMarrowResponsePathways to PathogensConverge
on Interleukin-6
Hematopoietic stem and progenitor cells (HSPCs) were known to be directly
and indirectly influenced by infections. We now know that they can make
and respond to their own growth and differentiation factors such as IL-6. As
another mechanism, activated T cells can produce interferon that causes
mesenchymal stemcells (MSCs) tomake IL-6. These and other processes pro-
mote production of innate effector cells such as monocytes (Mono) and den-
dritic cells (DC) while lymphopoiesis is inhibited. Meanwhile, hematopoietic
stem cells (HSCs) can be driven into cycle and mobilized to other tissues.
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tensively studied with respect
to hematopoieisis, but typi-
cally in the context of direct
effects on HSPCs. Docu-
mented responses include
the activation of primitive
cells that could have survival
value, but persistent stimula-
tion during chronic infections
is generally harmful (Bal-
dridge et al., 2011). Given
the extensive clinical use of
IFNs, it will be important to
identify situations where IL-6
production by MSCs could
be important. It is expected
that different pathogens can
alter blood cell formation
in many other ways. For
example, in E. muris infection,
it is CD4+ T cells within bone
marrow that utilize TLR/
MyD88 pathway stimulation
to produce IFNg that in turn
promotes hematopoetic pro-
genitor cell expansion (Zhanget al., 2013).
The studies by Zhao et al. and Schu¨rch
et al. demonstrate how technical
advances and innovation can be used to
dissect complicated processes.
Although extremely rare, stem and pro-
genitor cells can be divided into subsets
according to phenotypes and functions
(Copley et al., 2012). Until recently, this
heterogeneity could be fully appreciated
only with tedious single-cell trans-
plants. Now, barcoding and proteomics
approaches can provide new insight into
the nature and significance of that diver-
sity. It is remarkable that individual
HSPCs in the Baltimore study differed
with respect to numbers, amounts, and416 Cell Stem Cell 14, April 3, 2014 ª2014 Elnature of cytokines made. Perhaps the
progenitors are poised to respond with a
repertoire of outcomes, thus providing
protection from a large assortment of
pathogens.
Immunostaining of marrow sections is
difficult, but a number of labs can now
localize cytokine-producing cells in rela-
tion to components of HSPC niches
(Morrison and Scadden, 2014). Thus, an
immediate question is where IL-6-pro-
ducing cells reside in marrow of normal
and infected animals. The authors of
these new studies suggest they will be
in defined niches where local cytokine
concentrations can become high. Onesevier Inc.has to be impressed at the
growing number of ways
the marrow can respond to
life-threatening infections.ACKNOWLEDGMENTS
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